← Back to Search

Dopamine Agonist

AP CD/LD for Parkinson's Disease

Phase 3
Waitlist Available
Led By Peter LeWitt, MD
Research Sponsored by Intec Pharma Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Study Summary

The purpose of this study is to allow evaluation of long-term clinical effect and safety outcome of treatment with AP-CD/LD, as well as to allow patients to benefit from extended treatment duration with AP-CD/LD after they have successfully completed the Phase 3 core study IN 11 004 ('core study', a phase III, multicenter, randomized, double-blind, double-dummy, active-controlled Phase 3 study to assess the safety and efficacy of AP CD/LD versus IR CD/LD in fluctuating PD patients).

Eligible Conditions
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Unified Parkinson's Disease Rating Scale (UPDRS)
Secondary outcome measures
Change in Parkinson's disease Questionnaire - 39 items (PDQ39).
Safety (Adverse Events, Safety laboratory, Vital signs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: AP CD/LDExperimental Treatment1 Intervention
Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d

Find a Location

Who is running the clinical trial?

Intec Pharma Ltd.Lead Sponsor
6 Previous Clinical Trials
611 Total Patients Enrolled
Peter LeWitt, MDPrincipal InvestigatorHenry Ford Hospital - West Bloomfield

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
2016. "A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02615873.
All > Parkinson
~53 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top